Piper Jaffray Starts CRISPR Therapeutics (CRSP) at Overweight
Tweet
Share
E-mailGet Alerts CRSP Hot Sheet
Price: $56.82 --0%
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 7 | New: 26
Rating Summary:
19 Buy, 14 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 4 | Down: 7 | New: 26
Join SI Premium – FREE
Piper Jaffray initiated coverage on CRISPR Therapeutics (NASDAQ: CRSP) with an Overweight rating and a price target of $21.00.
For an analyst ratings summary and ratings history on CRISPR Therapeutics click here. For more ratings news on CRISPR Therapeutics click here.
Shares of CRISPR Therapeutics closed at $17.50 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cantor Fitzgerald Starts Tempus AI Inc (TEM) at Overweight
- Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'
- H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)
Create E-mail Alert Related Categories
New CoverageRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
